• 1
    Eddy DM. A manual for assessing health practices and designing practice guidelines: the explicit approach. Philadelphia: American College of Physicians, 1992.
  • 2
    American Gastoenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology 1995; 108: 925926.
  • 3
    Methodology Manual for ACC/AHA Guideline Writing Committees :Methodologies and Policies from the ACC/AHA Task Force on Practice Guidelines April 2006. 2006.
  • 4
    Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med 2003; 139: 493498.
  • 5
    Patrick CH. Alcohol, Culture, and Society. Durham, NC: Duke University Press; 1952.
  • 6
    Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. Semin Liver Dis 2004; 24: 217232.
  • 7
    Welte J, Barnes G, Wieczorek W, Tidwell MC, Parker J. Alcohol and gambling pathology among U.S. adults: prevalence, demographic patterns and comorbidity. J Stud Alcohol 2001; 62: 706712.
  • 8
    Caetano R, Tam T, Greenfield T, Cherpitel C, Midanik L. DSM-IV alcohol dependence and drinking in the U.S. population: a risk analysis. Ann Epidemiol 1997; 7: 542549.
  • 9
    Tam TW, Midanik LT. The effect of screening on prevalence estimates of alcohol dependence and social consequences. J Stud Alcohol 2000; 61: 617621.
  • 10
    Greenfield TK, Midanik LT, Rogers JD. A 10-year national trend study of alcohol consumption, 1984-1995: is the period of declining drinking over? Am J Public Health 2000; 90: 4752.
  • 11
    Hasin D, Paykin A, Meydan J, Grant B. Withdrawal and tolerance: prognostic significance in DSM-IV alcohol dependence. J Stud Alcohol 2000; 61: 431438.
  • 12
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, ed. 4. Washington, DC: American Psychiatric Association; 1994.
  • 13
    Chick J, Erickson CK. Conference summary: Consensus Conference on Alcohol Dependence and the Role of Pharmacotherapy in its Treatment. Alcohol Clin Exp Res 1996; 20: 391402.
  • 14
    Kitchens JM. Does this patient have an alcohol problem? JAMA 1994; 272: 17821787.
  • 15
    Grant BF, Harford TC, Dawson DA, Chou SP, Dufour M, Pickering RP. Prevalence of DSM-IV alcohol abuse and dependence: United States, 1992. Alcohol Health Research World 1992; 18: 243248.
  • 16
    Alcohol use and alcohol use disorders in the United States: main findings from the 2001-2002 National Epidemiologic Survey on Alcohol Use and Related Conditions (NESARC). National Institutes of Health (U.S.); National Institute on Alcohol Abuse and Alcoholism (U.S.); CSR, Incorporated 2006 Bethesda, Md: National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism.
  • 17
    Yoon YH, Yi HY. Surveillance report #75: Liver Cirrhosis Mortality in the United States, 1970-2003. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2006.
  • 18
    Becker U, Gronbaek M, Johansen D, Sorensen TI. Lower risk for alcohol-induced cirrhosis in wine drinkers. HEPATOLOGY 2002; 35: 868875.
  • 19
    Pelletier S, Vaucher E, Aider R, Martin S, Perney P, Balmes JL, et al. Wine consumption is not associated with a decreased risk of alcoholic cirrhosis in heavy drinkers. Alcohol Alcohol 2002; 37: 618621.
  • 20
    Corrao G, Ferrari P, Zambon A, Torchio P. Are the recent trends in liver cirrhosis mortality affected by the changes in alcohol consumption? Analysis of latency period in European countries. J Stud Alcohol 1997; 58: 486494.
  • 21
    Midanik L. The validity of self-reported alcohol consumption and alcohol problems: a literature review. Br J Addict 1982; 77: 357382.
  • 22
    World Health Organization. Global Status Report on Alcohol 2004. Geneva, Switzerland: World Health Organization; 2004.
  • 23
    Ezzati M, Lopez A, Rodgers A, Vander Hoorn S, Murray C; the Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 13471360.
  • 24
    Lefkowitch JH. Morphology of alcoholic liver disease. Clin Liver Dis 2005; 9: 3753.
  • 25
    Mendez-Sanchez N, Meda-Valdes P, Uribe M. Alcoholic liver disease. An update. Ann Hepatol 2005; 4: 3242.
  • 26
    MacSween RN, Burt AD. Histologic spectrum of alcoholic liver disease. Semin Liver Dis 1986; 6: 221232.
  • 27
    Crabb DW. Pathogenesis of alcoholic liver disease: newer mechanisms of injury. Keio J Med 1999; 48: 184188.
  • 28
    Lieber CS, Jones DP, Decarli LM. Effects of prolonged ethanol intake: production of fatty liver despite adequate diets. J Clin Invest 1965; 44: 10091021.
  • 29
    Mendenhall CL. Anabolic steroid therapy as an adjunct to diet in alcoholic hepatic steatosis. Am J Dig Dis 1968; 13: 783791.
  • 30
    Leevy CM. Fatty liver: a study of 270 patients with biopsy proven fatty liver and review of the literature. Medicine (Baltimore) 1962; 41: 249276.
  • 31
    Sorensen TI, Orholm M, Bentsen KD, Hoybye G, Eghoje K, Christoffersen P. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet 1984; 2: 241244.
  • 32
    Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346: 987990.
  • 33
    Worner TM, Lieber CS. Perivenular fibrosis as precursor lesion of cirrhosis. JAMA 1985; 254: 627630.
  • 34
    Savolainen V, Perola M, Lalu K, Penttila A, Virtanen I, Karhunen PJ. Early perivenular fibrogenesis–precirrhotic lesions among moderate alcohol consumers and chronic alcoholics. J Hepatol 1995; 23: 524531.
  • 35
    Nakano M, Worner TM, Lieber CS. Perivenular fibrosis in alcoholic liver injury: ultrastructure and histologic progression. Gastroenterology 1982; 83: 777785.
  • 36
    MacSween RN, Scott AR. Hepatic cirrhosis: a clinico-pathological review of 520 cases. J Clin Pathol 1973; 26: 936942.
  • 37
    Orrego H, Blake JE, Blendis LM, Medline A. Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 1987; 92: 208214.
  • 38
    Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet 1981; 1: 707711.
  • 39
    Ishak KG, Zimmerman HJ, Ray MB. Alcoholic liver disease: pathologic, pathogenetic and clinical aspects. Alcohol Clin Exp Res 1991; 15: 4566.
  • 40
    Christoffersen P, Nielsen K. Histological changes in human liver biopsies from chronic alcoholics. Acta Pathol Microbiol Scand A 1972; 80: 557565.
  • 41
    Mendenhall CL. Alcoholic hepatitis. Clin Gastroenterol 1981; 10: 417441.
  • 42
    Trabut JB, Plat A, Thepot V, Fontaine H, Vallet-Pichard A, Nalpas B, et al. Influence of liver biopsy on abstinence in alcohol-dependent patients. Alcohol Alcohol 2008; 43: 559563.
  • 43
    Alexander JF, Lischner MW, Galambos JT. Natural history of alcoholic hepatitis. II. The long-term prognosis. Am J Gastroenterol 1971; 56: 515525.
  • 44
    Bird GL, Williams R. Factors determining cirrhosis in alcoholic liver disease. Mol Aspects Med 1988; 10: 97105.
  • 45
    Galambos JT. Natural history of alcoholic hepatitis. 3. Histological changes. Gastroenterology 1972; 63: 10261035.
  • 46
    Savolainen VT, Liesto K, Mannikko A, Penttila A, Karhunen PJ. Alcohol consumption and alcoholic liver disease: evidence of a threshold level of effects of ethanol. Alcohol Clin Exp Res 1993; 17: 11121117.
  • 47
    Becker U, Deis A, Sorensen TI, Gronbaek M, Borch-Johnsen K, Muller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. HEPATOLOGY 1996; 23: 10251029.
  • 48
    Kamper-Jorgensen M, Gronbaek M, Tolstrup J, Becker U. Alcohol and cirrhosis: dose–response or threshold effect? J Hepatol 2004; 41: 2530.
  • 49
    Ramstedt M. Per capita alcohol consumption and liver cirrhosis mortality in 14 European countries. Addiction 2001; 96 ( Suppl. 1): S19;S33.
  • 50
    Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41: 845850.
  • 51
    Day CP. Who gets alcoholic liver disease: nature or nurture? J R Coll Physicians Lond 2000; 34: 557562.
  • 52
    Lu XL, Luo JY, Tao M, Gen Y, Zhao P, Zhao HL, et al. Risk factors for alcoholic liver disease in China. World J Gastroenterol 2004; 10: 24232426.
  • 53
    Wechsler H, Austin SB. Binge drinking: the five/four measure. J Stud Alcohol 1998; 59: 122124.
  • 54
    Barrio E, Tome S, Rodriguez I, Gude F, Sanchez-Leira J, Perez-Becerra E, et al. Liver disease in heavy drinkers with and without alcohol withdrawal syndrome. Alcohol Clin Exp Res 2004; 28: 131136.
  • 55
    Sato N, Lindros KO, Baraona E, Ikejima K, Mezey E, Jarvelainen HA, et al. Sex difference in alcohol-related organ injury. Alcohol Clin Exp Res 2001; 25: 40S45S.
  • 56
    Baraona E, Abittan CS, Dohmen K, Moretti M, Pozzato G, Chayes ZW, et al. Gender differences in pharmacokinetics of alcohol. Alcohol Clin Exp Res 2001; 25: 502507.
  • 57
    Frezza M, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 1990; 322: 9599.
  • 58
    Lelbach WK. Epidemiology of alcoholic liver disease. Prog Liver Dis 1976; 5: 494515.
  • 59
    Lelbach WK. Quantitative aspects of drinking in alcoholic liver cirrhosis. In: Khanna JM, Israel Y, and Kalant H, eds. Alcoholic Liver Pathology. Volume Toronto. Toronto: Alcoholism and Drug Addiction Research Foundation of Ontario; 1975. : 118.
  • 60
    Stewart SH. Racial and ethnic differences in alcohol-associated aspartate aminotransferase and gamma-glutamyltransferase elevation. Arch Intern Med 2002; 162: 22362239.
  • 61
    Stinson FS, Grant BF, Dufour MC. The critical dimension of ethnicity in liver cirrhosis mortality statistics. Alcohol Clin Exp Res 2001; 25: 11811187.
  • 62
    Wickramasinghe SN, Corridan B, Izaguirre J, Hasan R, Marjot DH. Ethnic differences in the biological consequences of alcohol abuse: a comparison between south Asian and European males. Alcohol Alcohol 1995; 30: 675680.
  • 63
    Mendenhall C, Roselle GA, Gartside P, Moritz T. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin Exp Res 1995; 19: 635641.
  • 64
    Leevy CM, Moroianu SA. Nutritional aspects of alcoholic liver disease. Clin Liver Dis 2005; 9: 6781.
  • 65
    Mezey E. Dietary fat and alcoholic liver disease. HEPATOLOGY 1998; 28: 901905.
  • 66
    Iturriaga H, Bunout D, Hirsch S, Ugarte G. Overweight as a risk factor or a predictive sign of histological liver damage in alcoholics. Am J Clin Nutr 1988; 47: 235238.
  • 67
    Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. HEPATOLOGY 1997; 25: 108111.
  • 68
    Uhl GR, Liu QR, Walther D, Hess J, Naiman D. Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. Am J Hum Genet 2001; 69: 12901300.
  • 69
    Brown K. Alcohol hepatotoxicity: a genotypic predisposition? Am J Gastroenterol 1992; 87: 677678.
  • 70
    Day CP, Bassendine MF. Genetic predisposition to alcoholic liver disease. Gut 1992; 33: 14441447.
  • 71
    Goodwin DW, Schulsinger F, Hermansen L, Guze SB, Winokur G. Alcohol problems in adoptees raised apart from alcoholic biological parents. Arch Gen Psychiatry 1973; 28: 238243.
  • 72
    Kaprio J, Koskenvuo M, Langinvainio H, Romanov K, Sarna S, Rose RJ. Social and genetic influences on drinking patterns of adult men: a study of 5638 Finnish twin brothers. Alcohol Alcohol Suppl 1987; 1: 373377.
  • 73
    Reed T, Page WF, Viken RJ, Christian JC. Genetic predisposition to organ-specific endpoints of alcoholism. Alcohol Clin Exp Res 1996; 20: 15281533.
  • 74
    McClain CJ, Song Z, Barve SS, Hill DB, Deaciuc I. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004; 287: G497G502.
  • 75
    Monzoni A, Masutti F, Saccoccio G, Bellentani S, Tiribelli C, Giacca M. Genetic determinants of ethanol-induced liver damage. Mol Med 2001; 7: 255262.
  • 76
    Degos F. Hepatitis C and alcohol. J Hepatol 1999; 31 ( Suppl. 1): 113118.
  • 77
    Monto A, Patel K, Bostrom A, Pianko S, Pockros P, McHutchison JG, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. HEPATOLOGY 2004; 39: 826834.
  • 78
    Befrits R, Hedman M, Blomquist L, Allander T, Grillner L, Kinnman N, et al. Chronic hepatitis C in alcoholic patients: prevalence, genotypes, and correlation to liver disease. Scand J Gastroenterol 1995; 30: 11131118.
  • 79
    Harris DR, Gonin R, Alter HJ, Wright EC, Buskell ZJ, Hollinger FB, et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001; 134: 120124.
  • 80
    Levitsky J, Mailliard ME. Diagnosis and therapy of alcoholic liver disease. Semin Liver Dis 2004; 24: 233247.
  • 81
    Grant BF. Barriers to alcoholism treatment: reasons for not seeking treatment in a general population sample. J Stud Alcohol 1997; 58: 365371.
  • 82
    Eckardt MJ, Rawlings RR, Martin PR. Biological correlates and detection of alcohol abuse and alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 1986; 10: 135144.
  • 83
    McQuade WH, Levy SM, Yanek LR, Davis SW, Liepman MR. Detecting symptoms of alcohol abuse in primary care settings. Arch Fam Med 2000; 9: 814821.
  • 84
    D'Amico EJ, Paddock SM, Burnam A, Kung FY. Identification of and guidance for problem drinking by general medical providers: results from a national survey. Med Care 2005; 43: 229236.
  • 85
    Sharpe PC. Biochemical detection and monitoring of alcohol abuse and abstinence. Ann Clin Biochem 2001; 38: 652664.
  • 86
    Umbricht-Schneiter A, Santora P, Moore RD. Alcohol abuse: comparison of two methods for assessing its prevalence and associated morbidity in hospitalized patients. Am J Med 1991; 91: 110118.
  • 87
    Moore RD, Bone LR, Geller G, Mamon JA, Stokes EJ, Levine DM. Prevalence, detection, and treatment of alcoholism in hospitalized patients. JAMA 1989; 261: 403407.
  • 88
    Prytz H, Melin T. Identification of alcoholic liver disease or hidden alcohol abuse in patients with elevated liver enzymes. J Intern Med 1993; 233: 2126.
  • 89
    Girela E, Villanueva E, Hernandez-Cueto C, Luna JD. Comparison of the CAGE questionnaire versus some biochemical markers in the diagnosis of alcoholism. Alcohol Alcohol 1994; 29: 337343.
  • 90
    Levine J. The relative value of consultation, questionnaires and laboratory investigation in the identification of excessive alcohol consumption. Alcohol Alcohol 1990; 25: 539553.
  • 91
    Helander A, Eriksson CJ. Laboratory tests for acute alcohol consumption: results of the WHO/ISBRA Study on State and Trait Markers of Alcohol Use and Dependence. Alcohol Clin Exp Res 2002; 26: 10701077.
  • 92
    Aalto M, Seppa K. Use of laboratory markers and the audit questionnaire by primary care physicians to detect alcohol abuse by patients. Alcohol Alcohol 2005; 40: 520523.
  • 93
    Soderstrom CA, Smith GS, Kufera JA, Dischinger PC, Hebel JR, McDuff DR, et al. The accuracy of the CAGE, the Brief Michigan Alcoholism Screening Test, and the Alcohol Use Disorders Identification Test in screening trauma center patients for alcoholism. J Trauma 1997; 43: 962969.
  • 94
    Skinner HA, Sheu WJ. Reliability of alcohol use indices. The Lifetime Drinking History and the MAST. J Stud Alcohol 1982; 43: 11571170.
  • 95
    Aertgeerts B, Buntinx F, Kester A. The value of the CAGE in screening for alcohol abuse and alcohol dependence in general clinical populations: a diagnostic meta-analysis. J Clin Epidemiol 2004; 57: 3039.
  • 96
    Bataille V, Ruidavets JB, Arveiler D, Amouyel P, Ducimetiere P, Perret B, et al. Joint use of clinical parameters, biological markers and CAGE questionnaire for the identification of heavy drinkers in a large population-based sample. Alcohol Alcohol 2003; 38: 121127.
  • 97
    Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption–II. Addiction 1993; 88: 791804.
  • 98
    Fiellin DA, Reid MC, O'Connor PG. Screening for alcohol problems in primary care: a systematic review. Arch Intern Med 2000; 160: 19771989.
  • 99
    MacKenzie D, Langa A, Brown TM. Identifying hazardous or harmful alcohol use in medical admissions: a comparison of audit, cage and brief mast. Alcohol Alcohol 1996; 31: 591599.
  • 100
    Bradley KA, Bush KR, McDonell MB, Malone T, Fihn SD. Screening for problem drinking: Comparison of CAGE and AUDIT. J Gen Intern Med 1998; 13: 379388.
  • 101
    Steinbauer JR, Cantor SB, Holzer CE III, Volk RJ. Ethnic and sex bias in primary care screening tests for alcohol use disorders. Ann Intern Med 1998; 129: 353362.
  • 102
    Helping Patients Who Drink Too Much: A Clinician's Guide. U.S. Department of Health and Human Services, National Institute of Health, National Institute on Alcohol Abuse and Alcoholism; 2005.
  • 103
    U.S. Preventive Services Task Force (USPSTF). Screening and behavioral counselling interventions in primary care to reduce alcohol misuse. Recommendation Statement. 2004.
  • 104
    Au DH, Kivlahan DR, Bryson CL, Blough D, Bradley KA. Alcohol screening scores and risk of hospitalizations for GI conditions in men. Alcohol Clin Exp Res 2007; 31: 443451.
  • 105
    Yersin B, Nicolet JF, Dercrey H, Burnier M, van Melle G, Pécoud A. Screening for excessive alcohol drinking. Comparative value of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume. Arch Intern Med 1995; 155: 19071911.
  • 106
    Conigrave KM, Degenhardt LJ, Whitfield JB, Saunders JB, Helander A, Tabakoff B. CDT, GGT, and AST as markers of alcohol use: the WHO/ISBRA collaborative project. Alcohol Clin Exp Res 2002; 26: 332339.
  • 107
    Sillanaukee P, Massot N, Jousilahti P, Vartiainen E, Sundvall J, Olsson U, et al. Dose response of laboratory markers to alcohol consumption in a general population. Am J Epidemiol 2000; 152: 747751.
  • 108
    Alte D, Luedemann J, Rose HJ, John U. Laboratory markers carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume are not useful as screening tools for high-risk drinking in the general population: results from the Study of Health in Pomerania (SHIP). Alcohol Clin Exp Res 2004; 28: 931940.
  • 109
    Reynaud M, Schellenberg F, Loisequx-Meunier MN, Schwan R, Maradeix B, Planche F, et al. Objective diagnosis of alcohol abuse: compared values of carbohydrate-deficient transferrin (CDT), gamma-glutamyl transferase (GGT), and mean corpuscular volume (MCV). Alcohol Clin Exp Res 2000; 24: 14141419.
  • 110
    Poynard T, Zourabichvili O, Hilpert G, Naveau S, Poitrine A, Benatar C, et al. Prognostic value of total serum bilirubin/gamma-glutamyl transpeptidase ratio in cirrhotic patients. HEPATOLOGY 1984; 4: 324327.
  • 111
    Naveau S, Poynard T, Abella A, Pignon JP, Poitrine A, Agostini H, et al. Prognostic value of serum fibronectin concentration in alcoholic cirrhotic patients. HEPATOLOGY 1985; 5: 819823.
  • 112
    Chen J, Conigrave KM, Macaskill P, Whitfield JB, Irwig L. Combining carbohydrate-deficient transferrin and gamma-glutamyltransferase to increase diagnostic accuracy for problem drinking. Alcohol Alcohol 2003; 38: 574582.
  • 113
    Hannuksela ML, Liisanantti MK, Nissinen AE, Savolainen MJ. Biochemical markers of alcoholism. Clin Chem Lab Med 2007; 45: 953961.
  • 114
    Hartmann S, Aradottir S, Graf M, Wiesbeck G, Lesch O, Ramskogler K, et al. Phosphatidylethanol as a sensitive and specific biomarker: comparison with gamma-glutamyl transpeptidase, mean corpuscular volume and carbohydrate-deficient transferrin. Addict Biol 2007; 12: 8184.
  • 115
    Bortolotti F, De Paoli G, Tagliaro F. Carbohydrate-deficient transferrin (CDT) as a marker of alcohol abuse: a critical review of the literature 2001-2005. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 841: 96109.
  • 116
    Wurst FM, Alling C, Aradottir S, Pragst F, Allen JP, Weinmann W, et al. Emerging biomarkers: new directions and clinical applications. Alcohol Clin Exp Res 2005; 29: 465473.
  • 117
    Hock B, Schwarz M, Domke I, Grunert VP, Wuertemberger M, Schiemann U, et al. Validity of carbohydrate-deficient transferrin (%CDT), gamma-glutamyltransferase (gamma-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin. Addiction 2005; 100: 14771486.
  • 118
    Anttila P, Jarvi K, Latvala J, Romppanen J, Punnonen K, Niemela O. Biomarkers of alcohol consumption in patients classified according to the degree of liver disease severity. Scand J Clin Lab Invest 2005; 65: 141151.
  • 119
    Center for Substance Abuse Treatment. The Role of Biomarkers in the Treatment of Alcohol Use Disorders. Substance Abuse Treatment Advisory. Volume 5, Issue 4, September 2006. Accessed online at:
  • 120
    Menon KV, Gores GJ, Shah VH. Pathogenesis, diagnosis, and treatment of alcoholic liver disease. Mayo Clin Proc 2001; 76: 10211029.
  • 121
    Nalpas B, Vassault A, Charpin S, Lacour B, Berthelot P. Serum mitochondrial aspartate aminotransferase as a marker of chronic alcoholism: diagnostic value and interpretation in a liver unit. HEPATOLOGY 1986; 6: 608614.
  • 122
    Uchida T, Kao H, Quispe-Sjogren M, Peters RL. Alcoholic foamy degeneration–a pattern of acute alcoholic injury of the liver. Gastroenterology 1983; 84: 683692.
  • 123
    Nanji AA, French SW, Mendenhall CL. Serum aspartate aminotransferase to alanine aminotransferase ratio in human and experimental alcoholic liver disease: relationship to histologic changes. Enzyme 1989; 41: 112115.
  • 124
    Cohen JA, Kaplan MM. The SGOT/SGPT ratio–an indicator of alcoholic liver disease. Dig Dis Sci 1979; 24: 835838.
  • 125
    Niemela O. Biomarkers in alcoholism. Clin Chim Acta 2007; 377: 3949.
  • 126
    Nyblom H, Berggren U, Balldin J, Olsson R. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol 2004; 39: 336339.
  • 127
    de Bruyn G, Graviss EA. A systematic review of the diagnostic accuracy of physical examination for the detection of cirrhosis. BMC Med Inform Decis Mak 2001; 1: 6.
  • 128
    Leung NW, Farrant P, Peters TJ. Liver volume measurement by ultrasonography in normal subjects and alcoholic patients. J Hepatol 1986; 2: 157164.
  • 129
    Hamberg KJ, Carstensen B, Sorensen TI, Eghoje K. Accuracy of clinical diagnosis of cirrhosis among alcohol-abusing men. J Clin Epidemiol 1996; 49: 12951301.
  • 130
    Cozzolino G, Francica G, Lonardo A, Cerini R, Cacciatore L. Variability of the clinical and laboratory aspects in the presentation of chronic liver diseases in relation to their etiology. Analysis of a case study and review of the literature [in Italian]. Minerva Med 1985; 76: 753760.
  • 131
    Orrego H, Israel Y, Blake JE, Medline A. Assessment of prognostic factors in alcoholic liver disease: toward a global quantitative expression of severity. HEPATOLOGY 1983; 3: 896905.
  • 132
    Espinoza P, Ducot B, Pelletier G, Attali P, Buffet C, David B, et al. Interobserver agreement in the physical diagnosis of alcoholic liver disease. Dig Dis Sci 1987; 32: 244247.
  • 133
    Goldstein LI. Enlarged, tortuous arteries and hepatic bruit. JAMA 1968; 206: 25182520.
  • 134
    Han SH, Rice S, Cohen SM, Reynolds TB, Fong TL. Duplex doppler ultrasound of the hepatic artery in patients with acute alcoholic hepatitis. J Clin Gastroenterol 2002; 34: 573577.
  • 135
    Sherman HI, Hardison JE. The importance of a coexistent hepatic rub and bruit. A clue to the diagnosis of cancer in the liver. JAMA 1979; 241: 1495.
  • 136
    Zoneraich S, Zoneraich O. Diagnostic significance of abdominal arterial murmurs in liver and pancreatic disease. A phonoarteriographic study. Angiology 1971; 22: 197205.
  • 137
    Naylor CD. The rational clinical examination. Physical examination of the liver. JAMA 1994; 271: 18591865.
  • 138
    Klatsky AL, Chartier D, Udaltsova N, Gronningen S, Brar S, Friedman GD, et al. Alcohol drinking and risk of hospitalization for heart failure with and without associated coronary artery disease. Am J Cardiol 2005; 96: 346351.
  • 139
    Lazarevic AM, Nakatani S, Neskovic AN, Marinkovic J, Yasumura Y, Stojicic D, et al. Early changes in left ventricular function in chronic asymptomatic alcoholics: relation to the duration of heavy drinking. J Am Coll Cardiol 2000; 35: 15991606.
  • 140
    Preedy VR, Adachi J, Ueno Y, Ahmed S, Mantle D, Mullatti N, et al. Alcoholic skeletal muscle myopathy: definitions, features, contribution of neuropathy, impact and diagnosis. Eur J Neurol 2001; 8: 677687.
  • 141
    Estruch R, Nicolas JM, Villegas E, Junque A, Urbano-Marquez A. Relationship between ethanol-related diseases and nutritional status in chronically alcoholic men. Alcohol Alcohol 1993; 28: 543550.
  • 142
    Anderson P, Cremona A, Paton A, Turner C, Wallace P. The risk of alcohol. Addiction 1993; 88: 14931508.
  • 143
    Schiano TD, Bodian C, Schwartz ME, Glajchen N, Min AD. Accuracy and significance of computed tomographic scan assessment of hepatic volume in patients undergoing liver transplantation. Transplantation 2000; 69: 545550.
  • 144
    Bird GL. Investigation of alcoholic liver disease. Baillieres Clin Gastroenterol 1993; 7: 663682.
  • 145
    Vilgrain V. Ultrasound of diffuse liver disease and portal hypertension. Eur Radiol 2001; 11: 15631577.
  • 146
    Okazaki H, Ito K, Fujita T, Koike S, Takano K, Matsunaga N. Discrimination of alcoholic from virus-induced cirrhosis on MR imaging. AJR Am J Roentgenol 2000; 175: 16771681.
  • 147
    Awaya H, Mitchell DG, Kamishima T, Holland G, Ito K, Matsumoto T. Cirrhosis: modified caudate-right lobe ratio. Radiology 2002; 224: 769774.
  • 148
    Levin DM, Baker AL, Riddell RH, Rochman H, Boyer JL. Nonalcoholic liver disease. Overlooked causes of liver injury in patients with heavy alcohol consumption. Am J Med 1979; 66: 429434.
  • 149
    Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 2000; 14: 543548.
  • 150
    Hall PD. Pathological spectrum of alcoholic liver disease. Alcohol Alcohol Suppl 1994; 2: 303313.
  • 151
    Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996; 110: 18471853.
  • 152
    Nissenbaum M, Chedid A, Mendenhall C, Gartside P. Prognostic significance of cholestatic alcoholic hepatitis. VA Cooperative Study Group #119. Dig Dis Sci 1990; 35: 891896.
  • 153
    Chedid A, Mendenhall CL, Tosch T, Chen T, Rabin L, Garcia-Pont P, et al. Significance of megamitochondria in alcoholic liver disease. Gastroenterology 1986; 90: 18581864.
  • 154
    Tanaka T, Yabusako T, Yamashita T, Kondo K, Nishiguchi S, Kuroki T, et al. Contribution of hepatitis C virus to the progression of alcoholic liver disease. Alcohol Clin Exp Res 2000; 24: 112S116S.
  • 155
    Diehl AM, Goodman Z, Ishak KG. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988; 95: 10561062.
  • 156
    Mathurin P, Poynard T, Ramond MJ, Degolt C. Interet de la biopsie hepatique pour la selection des sujets suspects d'hepatitealcoolique aigue [Abstract]. Gastroenterol Clin Biol 1992; 16: A231.
  • 157
    Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193199.
  • 158
    Carithers RL Jr, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989; 110: 685690.
  • 159
    Mathurin P, Abdelnour M, Ramond MJ, Carbonell N, Fartoux L, Serfaty L, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. HEPATOLOGY 2003; 38: 13631369.
  • 160
    Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. HEPATOLOGY 2001; 33: 464470.
  • 161
    Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54: 11741179.
  • 162
    Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002; 2: 2.
  • 163
    Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004; 40: 897903.
  • 164
    Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005; 42: 700706.
  • 165
    Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Vasilieva L, Archimandritis AJ. Predicting utility of a model for end stage liver disease in alcoholic liver disease. World J Gastroenterol 2006; 12: 40204025.
  • 166
    Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. HEPATOLOGY 2005; 41: 353358.
  • 167
    Rincon D, Lo IO, Ripoll C, Gomez-Camarero J, Salcedo M, Catalina MV, et al. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis. Aliment Pharmacol Ther 2007; 25: 841848.
  • 168
    Mookerjee RP, Malaki M, Davies NA, Hodges SJ, Dalton RN, Turner C, et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. HEPATOLOGY 2007; 45: 6271.
  • 169
    Sougioultzis S, Dalakas E, Hayes PC, Plevris JN. Alcoholic hepatitis: from pathogenesis to treatment. Curr Med Res Opin 2005; 21: 13371346.
  • 170
    Lieber CS. New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. Curr Gastroenterol Rep 2004; 6: 6065.
  • 171
    Pessione F, Ramond MJ, Peters L, Pham BN, Batel P, Rueff B, et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003; 23: 4553.
  • 172
    Borowsky SA, Strome S, Lott E. Continued heavy drinking and survival in alcoholic cirrhotics. Gastroenterology 1981; 80: 14051409.
  • 173
    Brunt PW, Kew MC, Scheuer PJ, Sherlock S. Studies in alcoholic liver disease in Britain. I. Clinical and pathological patterns related to natural history. Gut 1974; 15: 5258.
  • 174
    Luca A, Garcia-Pagan JC, Bosch J, Feu F, Caballeria J, Groszmann RJ, et al. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology 1997; 112: 12841289.
  • 175
    Pares A, Caballeria J, Bruguera M, Torres M, Rodes J. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol 1986; 2: 3342.
  • 176
    Powell WJ Jr, Klatskin G. Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med 1968; 44: 406420.
  • 177
    Veldt BJ, Laine F, Guillygomarc'h A, Lauvin L, Boudjema K, Messner M, et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol 2002; 36: 9398.
  • 178
    Kelly JP, Kaufman DW, Koff RS, Laszlo A, Wiholm BE, Shapiro S. Alcohol consumption and the risk of major upper gastrointestinal bleeding. Am J Gastroenterol 1995; 90: 10581064.
  • 179
    Mackie J, Groves K, Hoyle A, Garcia C, Garcia R, Gunson B, et al. Orthotopic liver transplantation for alcoholic liver disease: a retrospective analysis of survival, recidivism, and risk factors predisposing to recidivism. Liver Transpl 2001; 7: 418427.
  • 180
    Miguet M, Monnet E, Vanlemmens C, Gache P, Messner M, Hruskovsky S, et al. Predictive factors of alcohol relapse after orthotopic liver transplantation for alcoholic liver disease. Gastroenterol Clin Biol 2004; 28: 845851.
  • 181
    Miller WR, Walters ST, Bennett ME. How effective is alcoholism treatment in the United States? J Stud Alcohol 2001; 62: 211220.
  • 182
    Pharmacotherapy for alcohol dependence. Summary, Evidence Report/Technology Assessment: Number 3, January 1999. Agency for Health Care Policy and Research. Rockville, MD.
  • 183
    Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2005; CD001867.
  • 184
    Palmer AJ, Neeser K, Weiss C, Brandt A, Comte S, Fox M. The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol Alcohol 2000; 35: 478492.
  • 185
    Mason BJ. Acamprosate in the treatment of alcohol dependence. Expert Opin Pharmacother 2005; 6: 21032115.
  • 186
    Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295: 20032017.
  • 187
    Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370: 19151922.
  • 188
    Galambos JT. Alcoholic hepatitis: its therapy and prognosis. Prog Liver Dis 1972; 4: 567588.
  • 189
    Chedid A, Mendenhall CL, Gartside P, French SW, Chen T, Rabin L. Prognostic factors in alcoholic liver disease. VA Cooperative Study Group. Am J Gastroenterol 1991; 86: 210216.
  • 190
    Saunders JB, Davis M, Williams R. Do women develop alcoholic liver disease more readily than men? Br Med J (Clin Res Ed) 1981; 282: 11401143.
  • 191
    Kondili LA, Taliani G, Cerga G, Tosti ME, Babameto A, Resuli B. Correlation of alcohol consumption with liver histological features in non-cirrhotic patients. Eur J Gastroenterol Hepatol 2005; 17: 155159.
  • 192
    Pendery ML, Maltzman IM, West LJ. Controlled drinking by alcoholics? New findings and a reevaluation of a major affirmative study. Science 1982; 217: 169175.
  • 193
    Mezey E. Interaction between alcohol and nutrition in the pathogenesis of alcoholic liver disease. Semin Liver Dis 1991; 11: 340348.
  • 194
    Mendenhall CL, Anderson S, Weesner RE, Goldberg SJ, Crolic KA. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984; 76: 211222.
  • 195
    Nompleggi DJ, Bonkovsky HL. Nutritional supplementation in chronic liver disease: an analytical review. HEPATOLOGY 1994; 19: 518533.
  • 196
    Calvey H, Davis M, Williams R. Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. J Hepatol 1985; 1: 141151.
  • 197
    Cabre E, Rodriguez-Iglesias P, Caballeria J, Quer JC, Sanchez-Lombrana JL, Pares A, et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. HEPATOLOGY 2000; 32: 3642.
  • 198
    Foody W, Heuman DD, Mihas AA, Schubert ML. Nutritional therapy for alcoholic hepatitis: new life for an old idea. Gastroenterology 2001; 120: 10531054.
  • 199
    Plauth M, Cabre E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J, et al. ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr 2006; 25: 285294.
  • 200
    Daures JP, Peray P, Bories P, Blanc P, Yousfi A, Michel H, et al. Corticoid therapy in the treatment of acute alcoholic hepatitis. Results of a meta-analysis [in French]. Gastroenterol Clin Biol 1991; 15: 223228.
  • 201
    Reynolds TB, Benhamou JP, Blake J, Naccarato R, Orrego H. Treatment of alcoholic hepatitis. Gastroenterol Int 1989; 2: 208216.
  • 202
    Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990; 113: 299307.
  • 203
    Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995; 37: 113118.
  • 204
    Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis–a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008; 27: 11671178.
  • 205
    Higgins J, Thompson S, Deeks J, Altman D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 2002; 7: 5161.
  • 206
    Sutton AJ, Higgins JP. Recent developments in meta-analysis. Stat Med 2008; 27: 625650.
  • 207
    Mathurin P, Mendenhall CL, Carithers RL Jr, Ramond MJ, Maddrey WC, Garstide P, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002; 36: 480487.
  • 208
    Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O'Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis–a randomised clinical trial. J Hepatol 2006; 44: 784790.
  • 209
    O'Shea R, McCullough AJ. Steroids or cocktails for alcoholic hepatitis. J Hepatol 2006; 44: 633636.
  • 210
    Uribe M, Schalm SW, Summerskill WH, Go VL. Oral prednisone for chronic active liver disease: dose responses and bioavailability studies. Gut 1978; 19: 11311135.
  • 211
    Mendenhall C, Roselle GA, Gartside P, Moritz T. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin Exp Res 1995; 19: 635641.
  • 212
    Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. HEPATOLOGY 2007; 45: 13481354.
  • 213
    Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 16371648.
  • 214
    Menon KV, Stadheim L, Kamath PS, Wiesner RH, Gores GJ, Peine CJ, et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004; 99: 255260.
  • 215
    Spahr L, Rubbia-Brandt L, Frossard JL, Giostra E, Rougemont AL, Pugin J, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002; 37: 448455.
  • 216
    Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. HEPATOLOGY 2004; 39: 13901397.
  • 217
    Mookerjee RP, Tilg H, Williams R, Jalan R. Infliximab and alcoholic hepatitis. HEPATOLOGY 2004; 40: 499500.
  • 218
    Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, et al. A randomized, double-blinded, placebo-controlled multicenter trial of Etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 19531960.
  • 219
    Schwabe RF, Brenner DA. Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol 2006; 290: G583G589.
  • 220
    Louvet A, Diaz E, Dharancy S, Coevoet H, Texier F, Thevenot T, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008; 48: 465470.
  • 221
    Bonkovsky HL, Fiellin DA, Smith GS, Slaker DP, Simon D, Galambos JT. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short-term effects on liver function. Am J Gastroenterol 1991; 86: 12001208.
  • 222
    Alvarez MA, Cabre E, Lorenzo-Zuniga V, Montoliu S, Planas R, Gassull MA. Combining steroids with enteral nutrition: a better therapeutic strategy for severe alcoholic hepatitis? Results of a pilot study. Eur J Gastroenterol Hepatol 2004; 16: 13751380.
  • 223
    Kulkarni K, Tran T, Medrano M, Yoffe B, Goodgame R. The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis. J Clin Gastroenterol 2004; 38: 453459.
  • 224
    O'Shea RS, McCullough AJ. Treatment of alcoholic hepatitis. Clin Liver Dis 2005; 9: 103134.
  • 225
    Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003; 38: 2431.
  • 226
    Wolff B, Machill K, Schumacher D, Schulzki I. MARS dialysis in decompensated alcoholic liver disease: a single-center experience. Liver Transpl 2007; 13: 11891192.
  • 227
    Tsuji Y, Kumashiro R, Ishii K, Arinaga T, Sakamoto Y, Tanabe R, et al. Severe alcoholic hepatitis successfully treated by leukocytapheresis: a case report. Alcohol Clin Exp Res 2003; 27: 26S31S.
  • 228
    Okubo K, Yoshizawa K, Okiyama W, Kontani K, Muto H, Umemura T, et al. Severe alcoholic hepatitis with extremely high neutrophil count successfully treated by granulocytapheresis. Intern Med 2006; 45: 155158.
  • 229
    Stickel F, Hoehn B, Schuppan D, Seitz HK. Review article: Nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther 2003; 18: 357373.
  • 230
    Marchesini G, Dioguardi FS, Bianchi GP, Zoli M, Bellati G, Roffi L, et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol 1990; 11: 92101.
  • 231
    Hirsch S, Bunout D, de la MP, Iturriaga H, Petermann M, Icazar G, et al. Controlled trial on nutrition supplementation in outpatients with symptomatic alcoholic cirrhosis. JPEN J Parenter Enteral Nutr 1993; 17: 119124.
  • 232
    Smith J, Horowitz J, Henderson JM, Heymsfield S. Enteral hyperalimentation in undernourished patients with cirrhosis and ascites. Am J Clin Nutr 1982; 35: 5672.
  • 233
    Kearns PJ, Young H, Garcia G, Blaschke T, O'Hanlon G, Rinki M, et al. Accelerated improvement of alcoholic liver disease with enteral nutrition. Gastroenterology 1992; 102: 200205.
  • 234
    Lochs H, Plauth M. Liver cirrhosis: rationale and modalities for nutritional support–the European Society of Parenteral and Enteral Nutrition consensus and beyond. Curr Opin Clin Nutr Metab Care 1999; 2: 345349.
  • 235
    Swart GR, Zillikens MC, van Vuure JK, van den Berg JW. Effect of a late evening meal on nitrogen balance in patients with cirrhosis of the liver. BMJ 1989; 299: 12021203.
  • 236
    Zillikens MC, van den Berg JW, Wattimena JL, Rietveld T, Swart GR. Nocturnal oral glucose supplementation. The effects on protein metabolism in cirrhotic patients and in healthy controls. J Hepatol 1993; 17: 377383.
  • 237
    Mezey E. Commentary on the hypermetabolic state and the role of oxygen in alcohol-induced liver injury. Recent Dev Alcohol 1984; 2: 135141.
  • 238
    Orrego H, Blake JE, Blendis LM, Compton KV, Israel Y. Long-term treatment of alcoholic liver disease with propylthiouracil. N Engl J Med 1987; 317: 14211427.
  • 239
    Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev 2002; CD002800.
  • 240
    Lieber CS. S-adenosyl-L-methionine: its role in the treatment of liver disorders. Am J Clin Nutr 2002; 76: 1183S1187S.
  • 241
    Mato JM, Camara J, Fernandez de PJ, Caballeria L, Coll S, Caballero A, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30: 10811089.
  • 242
    Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU, Perez-Mato I, Sanchez del Pino MM, Corrales FJ, et al. Importance of a deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of liver injury. Am J Clin Nutr 2002; 76: 1177S1182S.
  • 243
    Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev 2006; CD002235.
  • 244
    Kershenobich D, Uribe M, Suarez GI, Mata JM, Perez-Tamayo R, Rojkind M. Treatment of cirrhosis with colchicine. A double-blind randomized trial. Gastroenterology 1979; 77: 532536.
  • 245
    Morgan TR, Weiss DG, Nemchausky B, Schiff ER, Anand B, Simon F, et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology 2005; 128: 882890.
  • 246
    Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev 2005; CD002148.
  • 247
    Day CP. Apoptosis in alcoholic hepatitis: a novel therapeutic target? J Hepatol 2001; 34: 330333.
  • 248
    Austin AS, Mahida YR, Clarke D, Ryder SD, Freeman JG. A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis. Aliment Pharmacol Ther 2004; 19: 7988.
  • 249
    Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96: 17231732.
  • 250
    Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. HEPATOLOGY 2003; 37: 343350.
  • 251
    Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540543.
  • 252
    Mullen KD, Dasarathy S. Potential new therapies for alcoholic liver disease. Clin Liver Dis 1998; 2: 851881.
  • 253
    Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9: 105113.
  • 254
    Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases–a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 2005; 100: 25832591.
  • 255
    Burra P, Lucey MR. Liver transplantation in alcoholic patients. Transpl Int 2005; 18: 491498.
  • 256
    O'Grady JG. Liver transplantation alcohol related liver disease: (deliberately) stirring a hornet's nest! Gut 2006; 55: 15291531.
  • 257
    Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keefe EB, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Transplantation 1998; 66: 956962.
  • 258
    Perney P, Bismuth M, Sigaud H, Picot MC, Jacquet E, Puche P, et al. Are preoperative patterns of alcohol consumption predictive of relapse after liver transplantation for alcoholic liver disease? Transpl Int 2005; 18: 12921297.
  • 259
    Bellamy CO, DiMartini AM, Ruppert K, Jain A, Dodson F, Torbenson M, et al. Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation 2001; 72: 619626.
  • 260
    Zetterman RK. Liver transplantation for alcoholic liver disease. Clin Liver Dis 2005; 9: 171181.
  • 261
    Newton SE. Recidivism and return to work posttransplant. Recipients with substance abuse histories. J Subst Abuse Treat 1999; 17: 103108.
  • 262
    Mathurin P. Is alcoholic hepatitis an indication for transplantation? Current management and outcomes. Liver Transpl 2005; 11: S21S24.
  • 263
    Turner C. How much alcohol is in a ‘standard drink’? An analysis of 125 studies. Br J Addict 1990; 85: 11711175.
  • 264
    Brick J. Standardization of alcohol calculations in research. Alcohol Clin Exp Res 2006; 30: 12761287.
  • 265
    Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA 1984; 252: 19051907.
  • 266
    Porter HP, Simon FR, Pope CE, Volwiler W, Fenster LF. Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial. N Engl J Med 1971; 284: 13501355.
  • 267
    Helman RA, Temko MH, Nye SW, Fallon HJ. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Ann Intern Med 1971; 74: 311321.
  • 268
    Campra JL, Hamlin EM Jr, Kirshbaum RJ, Olivier M, Redeker AG, Reynolds TB. Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Ann Intern Med 1973; 79: 625631.
  • 269
    Blitzer BL, Mutchnick MG, Joshi PH, Phillips MM, Fessel JM, Conn HO. Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study. Am J Dig Dis 1977; 22: 477484.
  • 270
    Lesesne HR, Bozymski EM, Fallon HJ. Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloricements. Gastroenterology suppl 1978; 74: 169173.
  • 271
    Shumaker JB, Resnick RH, Galambos JT, Makopour H, Iber FL. A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. Am J Gastroenterol 1978; 69: 443449.
  • 272
    Depew W, Boyer T, Omata M, Redeker A, Reynolds T. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology 1980; 78: 524529.
  • 273
    Theodossi A, Eddleston AL, Williams R. Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut 1982; 23: 7579.
  • 274
    Mendenhall CL, Anderson S, Garcia-Pont P, Goldberg S, Kiernan T, Seeff LB, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984; 311: 14641470.
  • 275
    Bories P, Guedj JY, Mirouze D, Yousfi A, Michel H. Treatment of acute alcoholic hepatitis with prednisolone. 45 patients [in French]. Presse Med 1987; 16: 769772.
  • 276
    Ramond MJ, Poynard T, Rueff B, Mathurin P, Theodore C, Chaput JC, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 326: 507512.